Back to resultsIPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Primary Purpose
Leukemia
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
IPI-145
Follow-up Visit/Call
Sponsored by
About this trial
This is an interventional treatment trial for Leukemia focused on measuring Leukemia, Refractory Acute Lymphoblastic Leukemia, ALL, Burkitt's lymphoma, Lymphoblastic lymphoma, IPI-145
Eligibility Criteria
Inclusion Criteria:
- Previously treated ALL (including Burkitt's lymphoma, lymphoblastic lymphoma) in relapse or primary refractory. Patients with ALL or B or T cell origin may be treated. Patients in first relapse will be eligible regardless of the first remission duration. At least 10 patients in Salvage 1-2 will be treated to assess anti-ALL response more precisely.
- Age 16 years or older. Pediatric patients (<16 years old) will be allowed into the study after safety is established, that is at least 10 adult patients having received 1 or more cycles each.
- Zubrod performance status 0-3.
- Adequate liver function (bilirubin </= 1.5 mg/dL and SGPT or SGOT </= 3 x upper limit of normal [ULN], unless considered due to tumor), and renal function (creatinine </= 2 mg/dL). Even if organ function abnormalities are considered due to tumor, the upper limit for bilirubin is </= 2.0 mg/dL and creatinine </= 3 mg/dL.
- Male and female patients who are of childbearing potential agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy. Female patients need a negative serum or urine pregnancy test within 14 days of study start (applies only if patient is of childbearing potential. Non-childbearing is defined as > 1 year postmenopausal or surgically sterilized).
Exclusion Criteria:
- Patient with active heart disease (NYHA class >/= 3 as assessed by history and physical examination).
- Patients with a cardiac ejection fraction (as measured by either MUGA or echocardiogram) < 45% are excluded.
- Patients who receive other chemotherapy. Patients must have been off previous therapy for >/= 2 weeks and must have recovered from acute toxicity (to grade 1 or less) of all previous therapy prior to enrollment (consent signing). (Concurrent therapy for central nervous system [CNS] prophylaxis or treatment for CNS relapse is permitted). Treatment may start earlier if necessitated by the patient's medical condition (e.g. rapidly progressive disease) following discussion with the Principal Investigator.
- Prior allogeneic stem cell transplant in previous 3 months.
- Peripheral lymphoblasts > 50 x 109/L.
- Pregnant and breast-feeding patients are excluded.
- Patients with known hepatitis B or C are excluded.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
IPI-145
Arm Description
IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
Outcomes
Primary Outcome Measures
Overall Response Rate (ORR)
Primary endpoint for efficacy is overall response rate (ORR) defined as complete remission (CR), complete remission without recovery of counts (CRi), or partial remission (PR). Overall response evaluated at the end of the first two cycles.
Secondary Outcome Measures
Full Information
NCT ID
NCT02028039
First Posted
January 3, 2014
Last Updated
January 3, 2014
Sponsor
M.D. Anderson Cancer Center
Collaborators
Infinity Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02028039
Brief Title
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Official Title
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With IPI-145
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Withdrawn
Study Start Date
December 2013 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
Infinity Pharmaceuticals, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this clinical research study is to learn if IPI-145 can help to control the disease in patients with ALL. The safety of the study drug will also be studied.
Detailed Description
Study Drug Administration:
If patient is found to be eligible to take part in this study, they will receive IPI-145 by mouth twice a day for a month (30 days). Patient should swallow IPI-145 whole with a glass of water (about 8 ounces). If patient forgets to take a dose or if they vomit, they should not take another dose.
Each study cycle lasts 30 days.
Patient's dose of the study drug may change depending on any side effects they may have.
Study Visits:
Patient will have a physical exam within 1 week before Day 1 of each study cycle.
The first 2 cycles are called induction and all cycles after that are called consolidation cycles. Blood (about 1 tablespoon each time) will be drawn 1 to 3 times a week during induction (Cycles 1 and/or 2) and then at least 1 time a week during consolidation. How often blood will be drawn will be based on the study doctor's decision. These blood draws may be done at a clinic close to where patient lives if they choose.
Patient will have a bone marrow aspirate and/or biopsy between Days 14-21 (+/- 3 days) of Cycle 1 then every 1-2 cycles to check the status of the disease. Patient may have additional bone marrow aspirates and/or biopsies if their doctor thinks it is necessary.
Length of Study:
Patient may receive IPI-145 for up to 24 months if the doctor thinks it is in their best interest. Patient will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if they are unable to follow study directions.
Patient's participation on the study will be over after the follow-up visit/call.
Follow-up Visit/Call:
Patient will have a follow-up visit 30 days after their last dose of the study drug. At this visit, patient will be asked about any side effects they may be having. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
This is an investigational study. IPI-145 is not FDA approved or commercially available. Its use in this study is investigational.
Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
Leukemia, Refractory Acute Lymphoblastic Leukemia, ALL, Burkitt's lymphoma, Lymphoblastic lymphoma, IPI-145
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IPI-145
Arm Type
Experimental
Arm Description
IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
Intervention Type
Drug
Intervention Name(s)
IPI-145
Intervention Description
75 mg orally twice daily for 4 weeks.
Intervention Type
Behavioral
Intervention Name(s)
Follow-up Visit/Call
Intervention Description
Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
Primary Outcome Measure Information:
Title
Overall Response Rate (ORR)
Description
Primary endpoint for efficacy is overall response rate (ORR) defined as complete remission (CR), complete remission without recovery of counts (CRi), or partial remission (PR). Overall response evaluated at the end of the first two cycles.
Time Frame
60 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Previously treated ALL (including Burkitt's lymphoma, lymphoblastic lymphoma) in relapse or primary refractory. Patients with ALL or B or T cell origin may be treated. Patients in first relapse will be eligible regardless of the first remission duration. At least 10 patients in Salvage 1-2 will be treated to assess anti-ALL response more precisely.
Age 16 years or older. Pediatric patients (<16 years old) will be allowed into the study after safety is established, that is at least 10 adult patients having received 1 or more cycles each.
Zubrod performance status 0-3.
Adequate liver function (bilirubin </= 1.5 mg/dL and SGPT or SGOT </= 3 x upper limit of normal [ULN], unless considered due to tumor), and renal function (creatinine </= 2 mg/dL). Even if organ function abnormalities are considered due to tumor, the upper limit for bilirubin is </= 2.0 mg/dL and creatinine </= 3 mg/dL.
Male and female patients who are of childbearing potential agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy. Female patients need a negative serum or urine pregnancy test within 14 days of study start (applies only if patient is of childbearing potential. Non-childbearing is defined as > 1 year postmenopausal or surgically sterilized).
Exclusion Criteria:
Patient with active heart disease (NYHA class >/= 3 as assessed by history and physical examination).
Patients with a cardiac ejection fraction (as measured by either MUGA or echocardiogram) < 45% are excluded.
Patients who receive other chemotherapy. Patients must have been off previous therapy for >/= 2 weeks and must have recovered from acute toxicity (to grade 1 or less) of all previous therapy prior to enrollment (consent signing). (Concurrent therapy for central nervous system [CNS] prophylaxis or treatment for CNS relapse is permitted). Treatment may start earlier if necessitated by the patient's medical condition (e.g. rapidly progressive disease) following discussion with the Principal Investigator.
Prior allogeneic stem cell transplant in previous 3 months.
Peripheral lymphoblasts > 50 x 109/L.
Pregnant and breast-feeding patients are excluded.
Patients with known hepatitis B or C are excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan O'Brien, MD, BA
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Links:
URL
http://www.mdanderson.org
Description
University of Texas MD Anderson Cancer Center Website
Learn more about this trial
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
We'll reach out to this number within 24 hrs